Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

	Originally Reported			Adjustment			Restated
	Three Months Ended March 31, 2023			Three Months Ended March 31, 2023			Three Months Ended March 31, 2023
Research and development	$	5,234,999		$	249,146		$	5,484,145
Total operating expenses		6,735,553			249,146			6,984,699
Loss from operations		(6,735,553	)		(249,146	)		(6,984,699	)
Net loss		(6,602,543	)		(249,146	)		(6,851,689	)
Basic and diluted	$	(0.30	)	$	(0.01	)	$	(0.31	)

	Originally Reported			Adjustment			Restated
	Three Months Ended March 31, 2023			Three Months Ended March 31, 2023			Three Months Ended March 31, 2023
Cash flows from operating activities
Net loss	$	(6,602,543	)	$	(249,146	)	$	(6,851,689	)
Adjustments to reconcile net loss to net cash used in operating activities
Changes in operating assets and liabilities
Accrued expenses and other current liabilities		512,590			249,146			761,736
Net cash used in operating activities		(7,951,397	)		—			(7,951,397	)